Bristol Myers Squibb Presents New Long-term Data from the EMERGENT …
Oct 31, 2024 · PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced new topline results from the Phase 3 EMERGENT-4 and EMERGENT-5 open-label trials evaluating the long-term efficacy, safety, and tolerability of COBENFY™ (xanomeline and trospium chloride) in adults with schizophrenia over 52 weeks of treatment. Data were ...
Bristol Myers Squibb Shares EMERGENT-4, EMERGENT-5 Results …
Nov 1, 2024 · EMERGENT-4, a phase 3, 52-week, outpatient, open-label extension study, evaluated the long-term safety, tolerability, and efficacy of xanomeline trospium chloride in 156 adults with schizophrenia.
Bristol Myers presents new long-term data from EMERGENT …
Oct 31, 2024 · Bristol Myers (BMY) Squibb “announced new topline results from the Phase 3 EMERGENT-4 and EMERGENT-5 open-label trials evaluating the long-term efficacy, safety, and tolerability of COBENFY...
Bristol Myers Squibb - Bristol Myers Squibb Presents New Pooled …
Apr 6, 2024 · PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced interim long-term safety, tolerability and metabolic outcomes data from its Phase 3 EMERGENT program evaluating KarXT (xanomeline-trospium) in adults with schizophrenia.
Bristol Myers Squibb Presents New Long-term Data from the EMERGENT …
Oct 31, 2024 · PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced new topline results from the Phase 3 EMERGENT-4 and EMERGENT-5 open-label trials evaluating the long-term...
U.S. FDA Approves Over-the-Counter Designation for Emergent ...
GAITHERSBURG, Md., March 29, 2023 (GLOBE NEWSWIRE) — Today, Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved NARCAN ® Naloxone HCl Nasal Spray 4 mg as an over-the-counter (OTC) emergency treatment of opioid overdose.
Corporate news details
Sep 26, 2024 · COBENFY represents the first new pharmacological approach to treat schizophrenia in decades, with a mechanism of action distinct from current therapies. Approval is supported by data from the EMERGENT clinical program demonstrating statistically significant reductions of schizophrenia symptoms.
Harvey Weinstein Returns to Hospital For Emergent Treatment, …
6 days ago · Harvey Weinstein has been taken back to Bellevue Hospital for “emergent treatment” related to an “alarming blood test result,” his spokesperson and attorney said Monday.
Harvey Weinstein Hospitalized for ‘Emergent Treatment ... - Yahoo
5 days ago · Harvey Weinstein is back in the hospital after receiving an “alarming blood test result.” On Monday, Weinstein’s attorney confirmed that the disgraced mogul was receiving “emergent treatment”...
'Impressive' New Data on Novel Schizophrenia Hopeful KarXT - Medscape
May 8, 2024 · Results of the EMERGENT-3 trial confirm that the novel investigational antipsychotic xanomeline-trospium (KarXT, Karuna Therapeutics) is effective and well tolerated in adults with...